Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.

Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Abstract Text:

To facilitate the differential diagnosis of poorly differentiated metastatic carcinomas of unknown primary site, we evaluated p63 and cytokeratin (CK) 5/6 as immunohistochemical markers for squamous cell carcinomas. The study cases were as follows: squamous cell carcinoma of the lungs, head/neck, esophagus, cervix uteri, or anal canal, 73; non-squamous cell carcinomas of various primary sites, 141; and urothelial carcinoma, 20. We also tested 14 malignant mesotheliomas. Immunoreactivity for p63 was as follows: squamous cell carcinomas, 59 (81%); urothelial carcinoma, 14 (70%), most often with diffuse staining patterns; non-squamous cell carcinomas, 20 (14.2%), resulting in a specificity of 0.86 of p63 for squamous cell carcinomas. Coexpression of p63 and CK5/6 had a sensitivity of 0.77 and a specificity of 0.96 for squamous cell carcinomas. Increasing the minimal criterion of positive immunostaining for both markers to more than 50% of immunoreactive tumor cells resulted in a specificity of 0.99, although the sensitivity diminished to 0.66. All malignant mesotheliomas were negative for p63. Our data suggest that positive immunostaining for both p63 and CK5/6 in poorly differentiated metastatic carcinomas is highly predictive of a primary tumor of squamous epithelial origin.

Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: American journal of clinical pathology

VOLUME: 116

Page Numbers: 823-30

Journal Abbreviation: Am. J. Clin. Pathol.

ISSN: 0002-9173

DAY: 27

MONTH: Dec

YEAR: 2001

Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370470

Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Keywords Mesh Terms:

KEYWORDS: Tumor Suppressor Proteins

MESH TERMS: analysis

Chemical & Substance for Abstract: Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Information

Substance Name: Keratins

Registry Number: 68238-35-7

Grant and Affiliation Information for Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.

AFFILIATION: Institute of Pathology, Charité University Hospital, Berlin, Germany.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Clin Pathol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas Related Publications

• Borderline tumors of the ovary and peritoneal implants.
• Immunoreactivity of PTH-binding in intact bovine kidney tissue and cultured cortical kidney cells indicative for specific receptors.
• Mixed serous carcinoma of the endometrium with trophoblastic differentiation: analysis of the p53 tumor suppressor gene suggests stem cell origin.
• Molecular mechanisms and possibilities of overcoming drug resistance in gastrointestinal tumors.
• Molecular pathology of colorectal cancer: from phenotype to genotype.
• Morphological characteristics of tumors with humoral hypercalcemia of malignancy: functional morphology of PTHrP.
• The first Sino-German symposium on cancer research, Shanghai May 2007.
• Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.
• [Glycosuria in pregnancy or a prediabetic phase.]
• [Necessity of increasing autopsy frequency following the introduction of DRGs]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Pathology : The need for change.]
• [Pneumoperitoneum in infancy]
• [Study of efficiancy of teleconsultation: the Telepathology Consultation Service of the Professional Assoziation of German Pathologists for the screening program of breast carcinoma]
• [The cell in vitro.]
• [Thorn test in tuberculosis in childhood before and during isoniazid treatment.]
• [Toxoplasmosis from the standpoint of the obstetrician.]